Rapid Novor Inc Announces Residency in JLABS @ Toronto

Share Article

Rapid Novor Inc Announces Residency in JLABS @ Toronto

Rapid Novor Inc, the world's leader in antibody protein sequencing using mass spectrometry, today announces that it becomes a resident company in Johnson & Johnson Innovation, JLABS @ Toronto, located in the MaRS Centre in Toronto, Canada.

Rapid Novor Inc is a Kitchener-Waterloo based company dedicated to the development of antibody protein sequencing technologies. The company's mission is to advance life science for better human health with next generation protein sequencing. The company has successfully sequenced hundreds of monoclonal antibodies directly from the proteins and helped pharmaceutical companies in their antibody drug discovery.

"We are super excited in becoming a resident in JLABS @ Toronto. We are looking for ways to apply our core technologies to the medical diagnostic field to more sensitively and accurately detect and track protein markers in the blood." said Mingjie Xie, Co-founder and CEO of Rapid Novor Inc, "Joining JLABS @ Toronto is a critical step for us to fulfill our mission. We believe the mentorship, the resources and expertise in diagnostic and pharmaceutical across the ecosystem will help us grow to the next level."

JLABS @ Toronto is a 40,000 square-foot life science innovation center. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

About Rapid Novor Inc

Rapid Novor Inc is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needs to access the cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company's REmAb™ antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company's WILD™ service is the first commercially available service that can accurately distinguish the isomeric Isoleucine and Leucine using mass spectrometry. For more information, visit http://www.rapidnovor.com. Follow the company on Twitter @rapidnovor. 

Media Contact: Mingjie Xie, Rapid Novor Inc, +1 (519) 593-2260, mxie@rapidnovor.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Rapid Novor Inc

Share article on social media or email:

View article via:

Pdf Print